Atopic Dermatitis

Long-Term Laboratory Trends in Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Results from Measure Up 1 and 2 David G Cotter, Mona Shahriari, Diego Ruiz Dasilva, Erik Domingues, Shanthi Narla, Mark G Kirchhof, Rachel Goldberg, Meerat Oza, Deanne Dilley, Ayman Grada, Alan D Irvine < PREVIOUS POSTER NEXT POSTER > POSTER 13

Asthma Control in Patients with Moderate-To-Severe Atopic Dermatitis and Comorbid Asthma Receiving Lebrikizumab in a Real-World Setting: Interim Data from the AD-LIFE Non-Interventional Study Roland Buhl, Andreas Wollenberg, Thomas Bieber, Ralf Gutzmer, Afra Kempf, Sebastian Diemert, Laura Susok, Diamant Thaçi, Bob Geng, Felix Lauffer < PREVIOUS POSTER NEXT POSTER > POSTER 14

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis Jonathan Silverberg, Vivian Laquer, Peter Lio, Kim Papp, Alan Irvine, Andrew Blauvelt, Hany Elmaraghy, Louise DeLuca-Carter, Heidi Crane, Gaia Gallo, Evangeline Pierce, Yuxin Ding7 Amy S. Paller < PREVIOUS POSTER NEXT POSTER > POSTER 15

Lebrikizumab Provides Clinically Meaningful Response in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope1 Study Primary Results Diamant Thaçi, Alan Irvine, Christian Vestergaard, Christine Bangert, Jan Gutermuth, Helena Agell, Júlia Valls Bancells, Victor Sapena, Ruth Coll, Marjolein de Bruin-Weller < PREVIOUS POSTER NEXT POSTER > POSTER 16

Real-World Effectiveness of Lebrikizumab in Atopic Dermatitis Patients at 6 Months: Results from the PPD™ CorEvitas™ AD Registry in the United States and Canada Eric L. Simpson, Vimal H. Prajapati, William McCann, Evangeline Pierce, Alvin Li, Chien-Wen J. Choi, Bryce J. Wiley, Zach Dawson, Elsa Inman, Kayla Callahan, Jonathan I. Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 17

Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: First year of ADlong Long-Term Extension Trial Stephan Weidinger, Alan Irvine, Diamant Thaçi, Jacek C Szepietowski, Tilo Biedermann, Helena Agell, Yanislav Mihaylov, Belchin Kostov, Ruth Coll, William Romero, Kristian Reich < PREVIOUS POSTER NEXT POSTER > POSTER 18

Flare-Free Disease Control Up to 3 Years Following Lebrikizumab Treatment in Atopic Dermatitis Patients Achieving 16-Week Response: A Post-Hoc Analysis of the ADjoin Study Joseph Merola, Leon Kircik, Sebastien Barbarot, Jose Manuel Carrascosa, Stephan Weidinger, Peter Lio, Francis Corrado, Gaia Gallo, Yuxin Ding, Yi Li, Helena Agell, Jonathan I Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 19

Improvement in Time to Itch Relief After Use of Both a Lotion and Cream for Eczema Patients Thu Q. Nguyen, PhD; Sindhu Garimella MS; Christine Emesiani, PharmD; Matthew Meckfessel, PhD < PREVIOUS POSTER NEXT POSTER > POSTER 20

Long-Term Disease Control and Safety With Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Following Failure of Prior Topical Therapies: Results From the TRuE-AD4 Phase 3b Study Andreas Wollenberg, MD, PhD, H. Chih-ho Hong, MD, Elaine Agius, MD, PhD, Nina Magnolo, MD, Ketty Peris, MD, PhD, Eingun James Song, MD, Sébastien Barbarot, MD, PhD, Konstantin Popovic, PhD, Brett Angel, MD, Qian Li, PhD, José Manuel Carrascosa, MD, PhD < PREVIOUS POSTER NEXT POSTER > POST

Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: A Matching-Adjusted Indirect Comparison April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B. Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst < PREVIOUS POSTER NEXT POSTER > POSTER 22

Tralokinumab Treatment in Patients with Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results from the 32-Week Phase 3b ADHAND Trial Benjamin Ehst,1 Richard B. Warren,H. Chih-ho Hong, Dong Hun Lee, Andrei Metelitsa, Sebastian Volc, Marie Tauber, Farzaneh Safavimanesh, Ann-Marie Tindberg, Linda Stein-Gold < PREVIOUS POSTER NEXT POSTER > POSTER 23

Real-World Effectiveness and Tolerability of Tralokinumab in a Patient with Severe Atopic Dermatitis Refractory to Dupilumab and Janus Kinase Inhibitor Treatment Marley Cutrona, Alexandra K. Golant < PREVIOUS POSTER NEXT POSTER > POSTER 24

Efficacy and Safety of Tapinarof Cream 1% Once Daily Monotherapy in Adults and Children with Atopic Dermatitis: Pooled Results from ADORING 1 and 2 Jonathan I. Silverberg, Lawrence F. Eichenfield, Linda Stein Gold, Juan Camilo Arjona Ferreira, Robert Bissonnette < PREVIOUS POSTER NEXT POSTER > POSTER 25

Tailoring Treatment With Abrocitinib: Personalized Treatment Approaches Used in the JADE REAL Study Raj Chovatiya, Stephan Weidinger, Pinaki Biswas, Melissa Watkins, Herwig Koppensteiner < PREVIOUS POSTER NEXT POSTER > POSTER 26

52 Week Safety and Efficacy of Amlitelimab in Participants With Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis From the Open-Label Long-Term ATLANTIS Trial Emma Guttman-Yassky, Nina Magnolo, Maxwell Sauder, Delphine Staumont, Ken Igawa, Mahreen Ameen, Lin Ma, Lindsay Ackerman, Guy Gherardi, Pei Li, Melanie Espinasse, Karl Yen, Charlotte Bernigaud < PREVIOUS POSTER NEXT POSTER > POSTER 27

Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST-1 and COAST-2 Phase 3 Trials Linda Stein Gold, H. Chih-ho Hong, Pedro Mendes-Bastos, Nina Magnolo, Jinhua Xu, Ken Igawa, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Benjamin Planquette < PREVIOUS POSTER NEXT POSTER > POSTER 28

Efficacy and Safety of Amlitelimab, a Nondepleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial Eric Simpson, Stephan Weidinger, Michael Cameron, Thomas Hubiche, Xinghua Gao, Yoko Kataoka, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Sonya Davey < PREVIOUS POSTER NEXT POSTER > POSTER 29

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison Martin Steinhoff, DirkJan Hijnen, Vimal H. Prajapati, Jensen Yeung, Patricia Guyot, Yann Cabon, Yingxin Xu, Zhixiao Wang, Kerry Noonan, Mike Bastian < PREVIOUS POSTER NEXT POSTER > POSTER 30

Dupilumab Monotherapy Improves Xerosis and Dyspigmentation in Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis Andrew F. Alexis, Orit Markowitz, Tiffany Mayo, Valerie D. Callender, Noah A. Levit, Changming Xia, Chien-Chia Chuang, Brad Shumel, Zhixiao Wang, Christopher Hartford < PREVIOUS POSTER NEXT POSTER > POSTER 31

Systemic Treatments' Outcomes for Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years: PEDISTAD 5-Year Result Amy S. Paller, Joel C. Joyce, Alan D. Irvine, Lawrence F. Eichenfield, Lin Ma, Lara Wine Lee, Marlies de Graaf, Sara Hamad, Marius Ardeleanu, Annie Zhang < PREVIOUS POSTER NEXT POSTER > POSTER 32

Impact of Dupilumab on Bone Mineralization Biomarker and Growth in Girls and Boys 6–11 Years With Severe Atopic Dermatitis Alan D. Irvine, Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Lisa A. Beck, Lin Ma, Annamaria Staiano, Wenying Deng, Stephane Levy, Mike Bastian, Sonya L. Cyr < PREVIOUS POSTER NEXT POSTER > POSTER 33

Sustained Improvement in Signs and Symptoms of Atopic Dermatitis in Adolescents and Adults Initiating Dupilumab in Real-World Practice: 5-Year Completer Interim Analysis from the PROSE Registry Hermenio C. Lima, Luz Fonacier, Benjamin Lockshin, Tien Q. Nguyen, Yonghao Ma, Kwinten Bosman, Andrew Korotzer < PREVIOUS POSTER NEXT POSTER > POSTER 34